Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 919-949-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 14 Sep. 2021 - 09. Dec 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 luciferase KeratinoSens™ test method)
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hessisches Ministerium für Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz, Wiesbaden, Germany
- Type of study:
- ARE-Nrf2 luciferase LuSens test method
Test material
- Reference substance name:
- 4-(5-Propyl-tetrahydropyran-2-yl)-phenol
- EC Number:
- 919-949-5
- Cas Number:
- 879544-24-8
- Molecular formula:
- C14 H20 O2
- IUPAC Name:
- 4-(5-Propyl-tetrahydropyran-2-yl)-phenol
- Test material form:
- solid: particulate/powder
Constituent 1
In vitro test system
- Details of test system:
- Lusens transgenic cell line [442D]
- Details on the study design:
- PREPARATION OF TEST SOLUTIONS
On the day of the experiment (immediately before treatment) the test item was dissolved in DMSO to prepare a stock solution. The highest test concentration for the dose finding assay was 2000 µM in accordance with the OECD guideline 442D.
For the MTT test (dose finding assay) twelve concentrations of the test item were analysed. Therefore, dilutions were prepared by 1:2 serial dilutions from the highest concentration. With reference to the CV75 parameter, the highest tested concentrations in the main experiments were 50 µM.
DOSE RANGE FINDING ASSAY:
The doses investigated in the main experiment (LuSens) were determined with a MTT test. The MTT test is based on the cleavage of the yellow tetrazolium salt MTT [=3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid] to form a blue-violet formazan dye by MTT reduction. One cytotoxicity experiment (dose finding assay) was performed to obtain a CV75.
APPLICATION OF THE TEST CHEMICAL AND CONTROL SUBSTANCES
- Number of replicates 3
- Number of repetitions 2
- Test chemical concentrations 20.1, 24.1, 28.9, 34.7, 41.7, 50.0 µM
- Application procedure
For the treatment of the cells in the main experiments, a stock solution of the test item and the controls were prepared. The solvent control DMSO (24 replicates), the positive control (five replicates) and the negative control (six replicates), as well as the test item concentrations (each three replicates) were subsequently diluted 1:25 in treatment medium. The treatment medium control (twelve replicates) was used undiluted. 24 h ± 30 min after seeding of the cells, seeding medium were removed and 150 µL of treatment medium were distributed in each well. Thereafter, 50 µL of the test item and control dilutions and the medium control were added into the corresponding wells. At the end of the incubation period of 48 ± 1 h under standard cell culture conditions, the cell cultures were microscopically evaluated for morphological alterations or precipitation.
- Exposure time 48 ± 1 h
- Study evaluation and decision criteria used
If the luciferase induction is ≥1.5-fold and statistically significant compared to the solvent control in at least 2 consecutive non-cytotoxic tested concentrations (cell viability ≥70%) and at least 3 tested concentrations are non-cytotoxic, the main experiment of the LuSens prediction is considered positive. If these conditions are met in 2 of 2 or in 2 of 3 main experiments, the LuSens prediction is considered positive, otherwise the LuSens prediction is considered negative. A negative result obtained with a test item that does not form a stable dispersion and was not tested up to 2000 μM (or 2000 μg/mL for test items with no defined MW) and for which no cytotoxicity is observed in any of the tested concentration should be considered as inconclusive (OECD 442D). If no clear dose-response curve or a biphasic dose-response curve is observed, the experiment should be repeated to verify whether this is specific to the test item or due to an experimental artefact. If the biphasic response (i.e. when the threshold of 1.5 is crossed twice) is reproducible in an independent verification experiment, the lower concentration of a ≥ 1.5 induction should be reported (i.e. when the threshold of 1.5 is crossed the first time).
- Description on study acceptance criteria
• The average luciferase activity induction obtained with the positive control, 120 μM EGDMA should be ≥2.5, and the positive control should have a relative cell viability ≥70% as compared to the solvent control.
• The average luciferase activity induction obtained with the negative control, 5000 μM lactic acid, as well as the basal expression of untreated cells should be <1.5-fold as compared to the average solvent control.
• The average coefficient of variation (CV%) of the luminescence reading for the solvent controls (DMSO) should be below 20% in each main experiment.
• At least three test item concentrations should have cell viability of at least 70% relative to the solvent controls. Moreover, in case a result is to be considered negative, at least one concentration should be cytotoxic, i.e. have a cell viability <70%, or the maximum concentration of 2000 μM (or 2000 μg/ mL for substances with no defined MW) should have been tested.
- Other:
SEEDING AND INCUBATION
Between 4 and 6 x 10^5 or 6 and 8 x 10^5 cells were seeded in 15 mL cultivation medium and pre-cultured at least twice a week in culture flasks (80-90% confluent). The cell density between approximately 80-90% should not be exceeded.
After microscopic assessment of the cells, the cells were washed at least twice with 10 mL Ca2+/Mg2+ free DPBS including EDTA. Thereafter, the cells were trypsinated with 1 to 2 mL 0.05% Trypsin/EDTA for approximately 5 min at 37 ± 1.5 °C and 5.0 ± 0.5 % CO2. The cells were resuspended in 10 mL cultivation medium to neutralise the trypsin.
For seeding of the cells, the cultivation medium was removed, and the cells were transferred into seeding medium. Each treatment well of a 96 well microtiter plate was seeded with 100 µL cell suspension (9000 to 11000 LuSens cells per well), except the well of the blank control. The cells were incubated for 24 h ± 30 min under standard cell culture conditions.
LUCIFERASE ACTIVITY MEASUREMENTS
The Steady-Glo® mix was be prepared by adding Steady-Glo® buffer to one bottle of Steady-Glo® substrate and mixing by inversion until the substrate was dissolved. The Steady-Glo® working solution was prepared by mixing one part of DPBS (without Ca2+/Mg2+) with one part of Steady-Glo® mix.
At the end of the incubation period (48 ± 1 h), the treatment medium was removed from the wells and the cells were washed at least twice with 200 µL DPBS including Ca2+/Mg2+. Thereafter, 200 µL of the Steady-Glo® working solution was added in each well. After slowly shaking of the microtiter plate for at least 10 min in the dark, the plate was transferred to a microplate reader and the luminescence was measured for 2 sec per well.
DATA EVALUATION
The doses investigated in the main experiment (LuSens) were determined with a MTT test. The MTT test is based on the cleavage of the yellow tetrazolium salt MTT [=3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid] to form a blue-violet formazan dye by MTT reduction. One cytotoxicity experiment (dose finding assay) was performed to obtain a CV75. The MTT working solution consists of two components, the MTT stock solution (5 mg/mL MTT in Ca2+/Mg2+ free PBS) and treatment medium. Both components were mixed immediately before application at a ratio of 1:10. For the treatment of the cells in the dose finding assay, a stock solution of the test item and the controls were prepared. The test item was dissolved in the solvent and 1:2 serially diluted in the solvent to obtain the desired test item concentrations (twelve concentrations). All values stated in the report are rounded values. The solvent (twelve replicates), the positive (two replicates) and the negative (three replicates) controls as well as the test item concentrations (each three replicates) were subsequently diluted 1:25 in treatment medium. The medium control (six replicates) was used undiluted.
24 h ± 30 min after seeding of the cells, the seeding medium was removed from the wells. Thereafter, 150 µL treatment medium were added per well and 50 µL of the test item dilutions, the solvent, negative and positive controls and the medium control were added to the wells, respectively. At the end of the incubation period of 48 ± 1 h under standard cell culture conditions, the cell cultures were microscopically evaluated for morphological alterations or precipitation.
At the end of the incubation period, treatment medium was removed from the wells and the cells were washed at least twice with 200 µL DPBS including Ca2+/Mg2+. Thereafter, 200 µL of the MTT working solution were added to each treatment well and the cells were incubated for 3 hours ± 30 min under standard cell culture conditions. After rinsing the MTT working solution, the cells of each well were treated with 100 µL MTT lysis agent (isopropanol with 0.04 N HCl) for at least 30 min, while gently shaking. Thereafter, the microplate was transferred to a Multimode Reader equipped with a 570 nm filter to measure the absorbance (reference wavelength 690 nm).
The quantity of formazan is presumably directly proportional to the number of viable cells, as monitored by the absorbance.
- Other: - Vehicle / solvent control:
- DMSO
- Negative control:
- DL-Lactic acid
- Positive control:
- EGDMA (120 M) [442D]
Results and discussion
- Positive control results:
- The average luciferase activity induction obtained with the positive control, 120 μM EGDMA was ≥2.5 (ME 1: 7.73; ME 2: 7.44) and statistically significant.
In vitro / in chemico
Resultsopen allclose all
- Key result
- Group:
- test chemical
- Run / experiment:
- run/experiment 1
- Parameter:
- other: luciferase induction
- Value:
- 614 %
- At concentration:
- 0.05 mM
- Cell viability:
- 96.28 % @ 50 µM
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Group:
- test chemical
- Run / experiment:
- run/experiment 2
- Parameter:
- RFI CD86>200 [442E]
- Value:
- 373 %
- At concentration:
- 0.05 mM
- Cell viability:
- 72.77 % @ 50 µM
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Outcome of the prediction model:
- positive [in vitro/in chemico]
- Other effects / acceptance of results:
- Acceptance criteria:
- The average luciferase activity induction obtained with the positive control, 120 μM EGDMA was ≥2.5 (ME 1: 7.73; ME 2: 7.44) and statistically significant.
- The positive control had a relative cell viability ≥70% as compared to the solvent control (ME 1: 117.31%; ME 2: 118.83%).
- The average luciferase activity induction obtained with the negative control, 5000 μM Lactic acid (ME 1: 1.34; ME 2: 1.13), as well as the basal expression of untreated cells was <1.5-fold as compared to the average solvent control (ME 1: 1.16; ME 2: 1.05).
- The average coefficient of variation (CV%) of the luminescence reading for the solvent controls (DMSO) was below 20% in each main experiment (ME 1: 8.9%; ME 2: 6.0%).
- At least three test item concentrations had a cell viability of at least 70% relative to the solvent controls.
The test mets the acceptance criteria.
Any other information on results incl. tables
Results of the main experiment 1 (cell viability)
Treatment group |
Concentration |
Absorbance (OD570) |
Mean OD570 |
SD OD570 |
Mean OD570blank corr. |
Cell viability [%] |
|||||||||
Well 1 |
Well 2 |
Well 3 |
Well 4 |
Well 5 |
Well 6 |
||||||||||
Blank |
|
|
|
0.022 |
|
|
|
|
|
|
|
|
|
||
Solvent control |
|
|
|
|
|
|
|
|
0.472 |
0.04 |
0.450 |
100.00 |
|||
Medium control |
|
|
|
|
|
|
|
|
0.556 |
0.05 |
0.534 |
118.52 |
|||
Positive control |
|
120 |
µM |
0.522 |
0.508 |
0.616 |
0.478 |
0.628 |
|
0.550 |
0.07 |
0.528 |
117.31 |
||
Negative control |
|
5000 |
µM |
0.510 |
0.397 |
0.509 |
0.455 |
0.491 |
0.472 |
0.472 |
0.04 |
0.450 |
99.98 |
||
Test item |
C1 |
20.1 |
µM |
0.568 |
0.443 |
0.505 |
|
|
|
0.505 |
0.06 |
0.483 |
107.31 |
||
C2 |
24.1 |
µM |
0.581 |
0.565 |
0.563 |
|
|
|
0.570 |
0.01 |
0.548 |
121.59 |
|||
C3 |
28.9 |
µM |
0.585 |
0.546 |
0.614 |
|
|
|
0.582 |
0.03 |
0.560 |
124.26 |
|||
C4 |
34.7 |
µM |
0.508 |
0.532 |
0.515 |
|
|
|
0.518 |
0.01 |
0.496 |
110.19 |
|||
C5 |
41.7 |
µM |
0.492 |
0.501 |
0.503 |
|
|
|
0.499 |
0.01 |
0.477 |
105.83 |
|||
C6 |
50.0 |
µM |
0.426 |
0.431 |
0.510 |
|
|
|
0.456 |
0.05 |
0.434 |
96.28 |
Results of the main experiment 1 (fold induction)
Treatment group |
Concentration |
Luminescence |
Mean luminescence |
SD luminescence |
Mean luminescence blank corr. |
Fold induction |
p-value, if significant (two sample |
|||||||||
Well 1 |
Well 2 |
Well 3 |
Well 4 |
Well 5 |
Well 6 |
|||||||||||
Blank |
|
|
|
118 |
|
|
|
|
|
|
|
|
|
|
||
Solvent control |
|
|
|
|
|
|
|
|
216.1 |
19.13 |
98.1 |
1.00 |
|
|||
Medium control |
|
|
|
|
|
|
|
|
232.2 |
15.49 |
114.2 |
1.16 |
|
|||
Positive control |
|
120 |
µM |
732 |
909 |
879 |
939 |
924 |
|
876.6 |
83.82 |
758.6 |
7.73 |
0.000 |
||
Negative control |
|
5000 |
µM |
229 |
281 |
236 |
236 |
251 |
266 |
249.8 |
20.25 |
131.8 |
1.34 |
|
||
Test item |
C1 |
20.1 |
µM |
480 |
510 |
480 |
|
|
|
490.0 |
17.32 |
372.0 |
3.79 |
0.006 |
||
C2 |
24.1 |
µM |
406 |
384 |
392 |
|
|
|
394.0 |
11.14 |
276.0 |
2.81 |
0.000 |
|||
C3 |
28.9 |
µM |
576 |
517 |
554 |
|
|
|
549.0 |
29.82 |
431.0 |
4.39 |
0.000 |
|||
C4 |
34.7 |
µM |
569 |
488 |
621 |
|
|
|
559.3 |
67.02 |
441.3 |
4.50 |
0.000 |
|||
C5 |
41.7 |
µM |
628 |
665 |
621 |
|
|
|
638.0 |
23.64 |
520.0 |
5.30 |
0.000 |
|||
C6 |
50.0 |
µM |
761 |
702 |
695 |
|
|
|
719.3 |
36.25 |
601.3 |
6.13 |
0.000 |
Results of the main experiment 2 (cell viability)
Treatment group |
Concentration |
Absorbance (OD570) |
Mean OD570 |
SD OD570 |
Mean OD570blank corr. |
Cell viability [%] |
|||||||||
Well 1 |
Well 2 |
Well 3 |
Well 4 |
Well 5 |
Well 6 |
||||||||||
Blank |
|
|
|
0.014 |
|
|
|
|
|
|
|
|
|
||
Solvent control |
|
|
|
|
|
|
|
|
0.491 |
0.05 |
0.477 |
100.00 |
|||
Medium control |
|
|
|
|
|
|
|
|
0.631 |
0.09 |
0.617 |
129.28 |
|||
Positive control |
|
120 |
µM |
0.573 |
0.789 |
0.604 |
0.486 |
0.454 |
|
0.581 |
0.13 |
0.567 |
118.83 |
||
Negative control |
|
5000 |
µM |
0.609 |
0.483 |
0.533 |
0.611 |
0.603 |
0.707 |
0.591 |
0.08 |
0.577 |
120.88 |
||
Test item |
C1 |
20.1 |
µM |
0.476 |
0.330 |
0.453 |
|
|
|
0.420 |
0.08 |
0.406 |
84.99 |
||
C2 |
24.1 |
µM |
0.486 |
0.366 |
0.419 |
|
|
|
0.424 |
0.06 |
0.410 |
85.82 |
|||
C3 |
28.9 |
µM |
0.492 |
0.374 |
0.436 |
|
|
|
0.434 |
0.06 |
0.420 |
87.99 |
|||
C4 |
34.7 |
µM |
0.477 |
0.356 |
0.459 |
|
|
|
0.431 |
0.07 |
0.417 |
87.29 |
|||
C5 |
41.7 |
µM |
0.460 |
0.392 |
0.413 |
|
|
|
0.422 |
0.03 |
0.408 |
85.41 |
|||
C6 |
50.0 |
µM |
0.408 |
0.319 |
0.357 |
|
|
|
0.361 |
0.04 |
0.347 |
72.77 |
Results of the main experiment 2 (fold induction)
Treatment group |
Concentration |
Luminescence |
Mean luminescence |
SD luminescence |
Mean luminescence blank corr. |
Fold induction |
p-value, if significant (two sample |
|||||||||
Well 1 |
Well 2 |
Well 3 |
Well 4 |
Well 5 |
Well 6 |
|||||||||||
Blank |
|
|
|
126 |
|
|
|
|
|
|
|
|
|
|
||
Solvent control |
|
|
|
|
|
|
|
|
209.2 |
12.51 |
83.2 |
1.00 |
|
|||
Medium control |
|
|
|
|
|
|
|
|
213.2 |
18.58 |
87.2 |
1.05 |
|
|||
Positive control |
|
120 |
µM |
835 |
739 |
769 |
717 |
665 |
|
745.0 |
63.04 |
619.0 |
7.44 |
0.000 |
||
Negative control |
|
5000 |
µM |
229 |
192 |
185 |
214 |
251 |
251 |
220.3 |
28.45 |
94.3 |
1.13 |
|
||
Test item |
C1 |
20.1 |
µM |
310 |
325 |
347 |
|
|
|
327.3 |
18.61 |
201.3 |
2.42 |
0.000 |
||
C2 |
24.1 |
µM |
370 |
333 |
340 |
|
|
|
347.7 |
19.66 |
221.7 |
2.67 |
0.000 |
|||
C3 |
28.9 |
µM |
495 |
347 |
392 |
|
|
|
411.3 |
75.87 |
285.3 |
3.43 |
0.030 |
|||
C4 |
34.7 |
µM |
384 |
362 |
392 |
|
|
|
379.3 |
15.53 |
253.3 |
3.05 |
0.000 |
|||
C5 |
41.7 |
µM |
377 |
333 |
370 |
|
|
|
360.0 |
23.64 |
234.0 |
2.81 |
0.025 |
|||
C6 |
50.0 |
µM |
495 |
406 |
406 |
|
|
|
435.7 |
51.38 |
309.7 |
3.72 |
0.005 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- In conclusion, the test item activated LuSens cells under the test conditions of this study. Therefore, the test item is considered positive for the second key event of the skin sensitisation AOP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
